Praxis Precision Medicines initiated with buy rating and $713 price target
PRAX•B. Riley initiated coverage of Praxis Precision Medicines with a buy rating and a $713 price target.
Related News

Dolby partners with Honda to bring Atmos audio to new AVANCIER SUV
HMC•

Oil prices gain as Houthi attacks on Riyadh raise supply concerns
USO•

NexPoint Real Estate Finance director Brian Mitts sells $56,750 in common shares
NREF•

Intuit Inc.: RBC cuts target price to $330 from $385
INTU•

Gold set for worst week in eight months as firm dollar, Fed hike bets weigh
GLD•